BioAtla IPO Presentation Deck

BA3021: ROR2 Safety Profile at 1.8mg/kg Q3W or 2Q3W bigatla Overview of adverse events in BA3021 Phase 1 trial AEs consistent with MMAE-based toxicity, including: - reversible myelosuppression - transient liver enzyme elevation - metabolic disturbances Characteristic Any AEs Related AES with CTCAE Grade 3 or 4¹ Any related serious AEs¹ Related AEs leading to death¹ Related AEs leading to treatment discontinuation¹ Few grade 3 or greater AES Patients administered 1.8mg/kg Q3W (d1) or 2Q3W (d1,8) (safety population) BA3021 1.8 mg/kg (Q3W) (N=3) 3 (100%) 1 (33%) Note: "As assessed by the investigator. Missing responses are counted as related 0 0 None of the related AEs led to treatment discontinuation 0 BA3021 1.8 mg/kg (2Q3W) (N=7) 7 (100%) 3 (43%) 2 (29%) 0 0 19

View entire presentation